Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091636 | 0.85 | PARP1 (0.40) | HTR2CHTR2BKDM4EALDH1A1CHRM5 | |
| SCHEMBL6089877 | 0.83 | PARP1 (0.39) | HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6090523 | 0.82 | TNKS2 (0.39) | HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6089480 | 0.81 | TNKS2 (0.42) | HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6091873 | 0.81 | MEN1 (0.42) | HTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL6091051 | 0.81 | PARP1 (0.34) | HCRTR1HCRTR2HTR2CHTR2B | |
| SCHEMBL6093312 | 0.81 | PARP1 (0.34) | HCRTR1HCRTR2HTR2CHTR2B | |
| SCHEMBL6090916 | 0.81 | PARP1 (0.34) | HCRTR1HCRTR2HTR2CHTR2B | |
| SCHEMBL6091303 | 0.81 | PARP1 (0.34) | HCRTR1HCRTR2HTR2CHTR2B | |
| SCHEMBL6090229 | 0.78 | ALDH1A1 (0.41) | HTR2CHTR2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1582520-A1 | NOVEL PARP INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | HCRTR1 4803/4885HCRTR2 4806/4885HTR2C 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.